Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma

Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma

Background: The gut microbiome plays a pivotal role in regulating immunity. Gastric acid suppressants (GAS) are known to alter the gut microbiome and might therefore modify response to immunotherapy in cancer patients. We estimated associations of GAS with recurrence-free survival (RFS) and distant...

Full description

Saved in:
Bibliographic Details
Main Authors: Emanuel Bührer, Nina Glassee, Michal Kicinski, Oliver J. Kennedy, Christian U. Blank, Georgina V. Long, Victoria G. Atkinson, Stéphane Dalle, Andrew M. Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye Boers-Sonderen, Anna Maria Di Giacomo, Alfonsus J.M. van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Sara Gandini, Sara Valpione, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandala
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:EJC Skin Cancer
Subjects:
Immunotherapy
Immune-checkpoint inhibitors
Pembrolizumab
Gastric acid suppressants
Online Access:http://www.sciencedirect.com/science/article/pii/S2772611825004483
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items